Finally, we performed a meta-analysis comparing the effects of BRCA2m on OS in prostate cancer patients, which suggested that prostate patients with BRCA2m had worse OS than BRCA2 wt (HR: 1.85 (95% CI = 1.07–3.21)). The gene discussed is BRCA2; the disease is prostatitis.